Soleno Therapeutics (NASDAQ:SLNO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Soleno Therapeutics (NASDAQ:SLNO) from a hold rating to a buy rating in a research report sent to investors on Saturday.

SLNO has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reduced their price objective on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Finally, Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $106.85.

Soleno Therapeutics Stock Performance

Soleno Therapeutics stock opened at $33.39 on Friday. The stock has a 50-day simple moving average of $40.50 and a 200 day simple moving average of $50.69. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of 145.18 and a beta of -3.16. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a 12-month low of $32.63 and a 12-month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, research analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Several institutional investors have recently modified their holdings of SLNO. Avoro Capital Advisors LLC raised its stake in shares of Soleno Therapeutics by 12.5% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after buying an additional 322,223 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Soleno Therapeutics in the fourth quarter valued at approximately $38,000. Seven Fleet Capital Management LP bought a new position in Soleno Therapeutics in the fourth quarter valued at approximately $6,023,000. Virtu Financial LLC acquired a new stake in Soleno Therapeutics during the 4th quarter worth $1,059,000. Finally, Empowered Funds LLC acquired a new stake in Soleno Therapeutics during the 4th quarter worth $69,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Analysts still show support: SLNO retains a consensus rating of “Moderate Buy,” which could limit downside if fundamentals or clinical updates improve. Analyst Consensus Article
• Neutral Sentiment: Market visibility: coverage notes that SLNO has gained attention in the Nasdaq composite today — this can amplify moves (both up and down) as momentum traders respond. Market Attention Article
• Negative Sentiment: Class‑action litigation: a securities class action has been filed alleging Soleno concealed drug safety risks and that the company’s November 2025 DCCR/VYKAT™ XR disclosures harmed investors. That complaint (and related press) is the core negative catalyst investors cite. Hagens Berman Article
• Negative Sentiment: Multiple law firms soliciting plaintiffs: numerous firms (Rosen, Glancy Prongay Wolke & Rotter, Faruqi & Faruqi, Levi & Korsinsky, Robbins Geller, Kaplan Fox, Schall, DJS, etc.) have issued notices reminding investors of a May 5, 2026 lead‑plaintiff deadline and encouraging filings — increasing media attention and legal risk premium on the stock. Rosen Notice
• Negative Sentiment: Put buying surge: unusually large options activity — ~5,314 put contracts traded (≈109% above typical put volume) — signals increased bearish positioning and hedging demand, which can amplify downward pressure on the share price. (Intraday options flow reported by market data.)

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.